Owing to their bone-binding characteristics, bisphosphonates target to the skeleton, where they primarily act by inhibiting osteoclastic bone resorption. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. It is not to be confused with After binding to bone mineral, the drugs are internalized into bone-resorbing osteoclasts by endocytosis. If enough BP has been incorporated into new bone formed during prior treatment, that bisphosphonate may be released and again inhibit bone resorption. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int. Great progress has been made over the past two decades in understanding the mechanism of action of the bisphosphonates. Evidence shows that they reduce the risk of fracture in post-menopausal women with osteoporosis.The uses of bisphosphonates include the prevention and treatment of In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis.Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment.After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.Bisphosphonates reduce the risk of fracture and bone painBisphosphonates can also reduce mortality in those with multiple myeloma and prostate cancer.Evidence suggests that the use of bisphosphonates would be useful in the treatment of Bisphosphonates have been used to reduce fracture rates in children with the disease Bisphosphonates, when administered intravenously for the treatment of cancer, have been associated with A number of cases of severe bone, joint, or musculoskeletal pain have been reported, prompting labeling changes.Some studies have identified bisphosphonate use as a risk factor for In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the Three meta analyses have evaluated whether bisphosphonate use is associated with an increased risk of esophageal cancer. 1995 Aug; 17 (2):137–144. Whether they directly affect other cell types such as osteoblasts, osteocytes, and tumor cells Corresponding author: R. Graham G. Russell, The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom.We use cookies to help provide and enhance our service and tailor content and ads.

Owing to their bone-binding characteristics, bisphosphonates target to the skeleton, where they primarily act by inhibiting osteoclastic bone resorption. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. It is not to be confused with After binding to bone mineral, the drugs are internalized into bone-resorbing osteoclasts by endocytosis. If enough BP has been incorporated into new bone formed during prior treatment, that bisphosphonate may be released and again inhibit bone resorption. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int. Great progress has been made over the past two decades in understanding the mechanism of action of the bisphosphonates. Evidence shows that they reduce the risk of fracture in post-menopausal women with osteoporosis.The uses of bisphosphonates include the prevention and treatment of In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis.Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment.After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.Bisphosphonates reduce the risk of fracture and bone painBisphosphonates can also reduce mortality in those with multiple myeloma and prostate cancer.Evidence suggests that the use of bisphosphonates would be useful in the treatment of Bisphosphonates have been used to reduce fracture rates in children with the disease Bisphosphonates, when administered intravenously for the treatment of cancer, have been associated with A number of cases of severe bone, joint, or musculoskeletal pain have been reported, prompting labeling changes.Some studies have identified bisphosphonate use as a risk factor for In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the Three meta analyses have evaluated whether bisphosphonate use is associated with an increased risk of esophageal cancer. 1995 Aug; 17 (2):137–144. Whether they directly affect other cell types such as osteoblasts, osteocytes, and tumor cells Corresponding author: R. Graham G. Russell, The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom.We use cookies to help provide and enhance our service and tailor content and ads.

Owing to their bone-binding characteristics, bisphosphonates target to the skeleton, where they primarily act by inhibiting osteoclastic bone resorption. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. It is not to be confused with After binding to bone mineral, the drugs are internalized into bone-resorbing osteoclasts by endocytosis. If enough BP has been incorporated into new bone formed during prior treatment, that bisphosphonate may be released and again inhibit bone resorption. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy Osteoporos Int. Great progress has been made over the past two decades in understanding the mechanism of action of the bisphosphonates. Evidence shows that they reduce the risk of fracture in post-menopausal women with osteoporosis.The uses of bisphosphonates include the prevention and treatment of In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are Bisphosphonates are recommended as a first line treatments for post-menopausal osteoporosis.Long-term treatment with bisphosphonates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment.After five years of medications by mouth or three years of intravenous medication among those at low risk, bisphosphonate treatment can be stopped.Bisphosphonates reduce the risk of fracture and bone painBisphosphonates can also reduce mortality in those with multiple myeloma and prostate cancer.Evidence suggests that the use of bisphosphonates would be useful in the treatment of Bisphosphonates have been used to reduce fracture rates in children with the disease Bisphosphonates, when administered intravenously for the treatment of cancer, have been associated with A number of cases of severe bone, joint, or musculoskeletal pain have been reported, prompting labeling changes.Some studies have identified bisphosphonate use as a risk factor for In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the Three meta analyses have evaluated whether bisphosphonate use is associated with an increased risk of esophageal cancer. 1995 Aug; 17 (2):137–144. Whether they directly affect other cell types such as osteoblasts, osteocytes, and tumor cells Corresponding author: R. Graham G. Russell, The Oxford University Institute of Musculoskeletal Sciences, The Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, Nuffield Orthopaedic Centre, Headington, Oxford, United Kingdom.We use cookies to help provide and enhance our service and tailor content and ads.